as 07-08-2024 1:32pm EST
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Founded: | 1994 | Country: | United States |
Employees: | N/A | City: | DENVER |
Market Cap: | 12.2B | IPO Year: | 1995 |
Target Price: | $144.33 | AVG Volume (30 days): | 1.0M |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 8.80 | EPS Growth: | 61.17 |
52 Week Low/High: | $71.51 - $147.93 | Next Earning Date: | 08-01-2024 |
Revenue: | $12,338,003,000 | Revenue Growth: | 5.77% |
Revenue Growth (this year): | 5.47% | Revenue Growth (next year): | 4.19% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
DESOER BARBARA J | DVA | Director | May 10 '24 | Sell | $138.81 | 5,030 | $698,214.30 | 10,954 | SEC Form 4 |
Rodriguez Javier | DVA | Chief Executive Officer | Feb 26 '24 | Sell | $126.11 | 67,603 | $8,525,130.40 | 488,697 | SEC Form 4 |
Rodriguez Javier | DVA | Chief Executive Officer | Feb 26 '24 | Sell | $126.87 | 7,397 | $938,467.01 | 481,300 | SEC Form 4 |
STAFFIERI MICHAEL DAVID | DVA | Chief Operating Officer, DKC | Feb 21 '24 | Sell | $119.81 | 29,488 | $3,533,025.10 | 37,687 | SEC Form 4 |
Waters Kathleen Alyce | DVA | Chief Legal & Pub. Affairs Off | Feb 21 '24 | Sell | $120.73 | 11,285 | $1,362,438.05 | 81,297 | SEC Form 4 |
HEARTY JAMES O | DVA | Chief Compliance Officer | Feb 16 '24 | Sell | $119.64 | 26,164 | $3,130,268.81 | 20,264 | SEC Form 4 |
DVA Breaking Stock News: Dive into DVA Ticker-Specific Updates for Smart Investing
Morningstar Research
3 days ago
Zacks
3 days ago
Zacks
3 days ago
Zacks
3 days ago
Zacks
4 days ago
Zacks
4 days ago
Zacks
5 days ago
Zacks
5 days ago
The information presented on this page, "DVA DaVita Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.